Key facts
- Shorla Oncology’s last known valuation is $90.3M (Oct 2023).
- It has raised $65.9M; the latest was Later Stage VC ($18.0M) in Jan 2026.
- Notable investors include Enterprise Ireland, Kurma Partners, Davycrest Nominees, Kellysan Enterprises, Local Enterprise — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Shorla Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Shorla Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shorla Oncology
Developer of oncology medicines designed to improve existing cancer treatments through reformulated and alternative presentations. The company develops products for rare and orphan cancers, including pediatric and ovarian indications, addressing gaps in availability and administration of established oncology drugs, enabling healthcare institutions to access treatments that resolve limitations with traditional formulations.
- Sector
- Healthcare
- HQ
- Clonmel, Ireland
- Founded
- 2018
- Employees
- 43
- Website
- shorlaoncology.com/
- Ownership
- Privately Held (backing)
Shorla Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shorla Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shorla Oncology in its N-PORT filings yet. We sweep new filings monthly.